Pharmaceutical - AstraZeneca


Current filters:


Popular Filters

226 to 250 of 319 results

AstraZeneca to invest $1.2 billion in Russia by 2017; Pharmstandard deal with AVVA


Anglo-Swedish drug major AstraZeneca (LSE: AZN) plans to invest up to $1.2 billion in its development…

AstraZenecaAVVA PharmaceuticalsEuropeFinancialMarkets & MarketingPharmaceuticalPharmstandardProduction

AstraZeneca presents mixed data on fostamatinib in RA


Shares of Anglo-Swedish drug major AstraZeneca (LSE: AZN) fell 2.1% to $47.88 in premarket US trading…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibPharmaceuticalResearchRigel Pharmaceuticals

EU Court of Justice dismisses AstraZeneca appeal on patent settlement


The European Union's highest court, the Court of Justice, yesterday dismissed the appeal of Anglo-Swedish…


News briefs from Bayer, AstraZeneca and Valeant/Galderma


German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America


USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

FDA approves Exelixis' Cometriq for rare thyroid cancer, as EMA accepts filing


There were two items of good news yesterday for US drug developer Exelixis' (Nasdaq: EXEL), the first…

AstraZenecaBiotechnologycabozantinibCaprelsaCometriqEuropeExelixisNorth AmericaOncologyPharmaceuticalRegulation

First success of selumetinib, a targeted therapy in most common NSCLC


A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists…

Array BioPharmaAstraZenecaOncologyPharmaceuticalResearchselumetinib

Big Pharma doing more for access to medicine in developing countries than two years ago


The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts…

AstraZenecaBayerGlaxoSmithKlineGlobalHealthcareJohnson & JohnsonMerck KGaAPharmaceuticalPricingResearch

Asthma preventive drugs market led by GlaxoSmithKline's Advair


The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

AstraZeneca and Bristol-Myers get first approval for diabetes drug Forxiga


There was good news for AstraZeneca (LSE: AZN) and Bristol-Myers Squibb (NYSE: BMY), with the European…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesEuropeForxigaPharmaceuticalRegulation

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Russian prostate cancer market expected to grow 6% annually from 2011 to 2016


The total number of diagnosed incident cases of prostate cancer in Russia will increase at five percent…

AstraZenecaBuserelinEuropeMarkets & MarketingOncologyPharm-SintezPharmaceuticalZoladex

£7 million funding for MRC-AstraZeneca compound collaboration


The UK's Medical Research Council (MRC) will today (October 31) announce £7 million ($11.3 billion)…


New CEO Pascal Soriot to get over $6 million for moving to AstraZeneca


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has made a regulatory disclosure following the grant…


News briefs: Bayer's Stivarga and AstraZeneca's Faslodex


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

AstraZeneca 3rd-qtr 2012 takes heavy hit from generics


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that group sales for the third…


AstraZeneca gains rights to sell Ironwood's IBS drug in China


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

AstraZeneca's Brilinta rolls out in India


The Indian subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched its patented…

Asia-PacificAstraZenecaBrilintaCardio-vascularMarkets & MarketingPharmaceutical

AstraZeneca partners with China's Pharmaron to accelerate drug discovery


Pharmaron, a China-based R&D service provider for the pharmaceutical and biotech industries with operations…


226 to 250 of 319 results

Back to top